GPC2-targeted CAR-T cell therapy

**GPC2-targeted CAR-T cell therapy** is an investigational cell therapy where patient or donor T cells are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen glypican-2 (GPC2), a cell-surface protein highly expressed in pediatric neuroblastoma and certain central nervous system embryonal tumors[2][8]. The CAR-T cells recognize and bind to GPC2 on tumor cells, leading to immune-mediated cytotoxicity. Preclinical engineering (notably using the CT3 single-chain variable fragment, CD28 hinge/transmembrane, and 4-1BB co-stimulatory domains) has maximized anti-tumor efficacy in neuroblastoma models[2]. Clinical trials are evaluating safety, dosing, and preliminary efficacy in relapsed/refractory neuroblastoma and medulloblastoma[1][3][4][7][9].

Brand names

GPC2-targeted CAR-T cell therapyGPC-2-targeted CAR-T cell therapyGPC 2-targeted CAR-T cell therapy

Other names

GPC2-targeted CAR-T cell therapyGPC-2-targeted CAR-T cell therapyGPC 2-targeted CAR-T cell therapyGPC2 CAR T cell therapyGPC-2 CAR T cell therapyGPC 2 CAR T cell therapyGPC2-CAR TGPC-2-CAR TGPC 2-CAR TGPC2-directed chimeric antigen receptor T cellsGPC-2-directed chimeric antigen receptor T cellsGPC 2-directed chimeric antigen receptor T cells